Insulet Corporation
Insulet Corporation Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
3 of 3 strong
The short version
- Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24%. - Adjusted EPS expected to increase by more than 25% in 2026.
From Insulet Corporation's Q2 FY26 earnings-call transcript · updated 30 May 2026.
Revenue & Sales Performance
- Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24%.
- U.S. Omnipod revenue expected to grow 20%-22% in 2026, driven by new customer starts, positive pricing, and sustained utilization.
- International Omnipod revenue forecast at 26%-28% growth in 2026, supported by new customer sites, price/mix benefits from DASH to Omnipod 5 transition, and geographic expansion (e.g., Spain launch H2 2026).
- 2027 growth to be supported by the launch of Omnipod 6 and full benefit of salesforce expansion.
- Algorithm improvements and Libre 3 Plus sensor integration expected to expand total addressable market (e.g., ~450,000 additional users in U.S.).
2 more points from Insulet Corporation's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Insulet Corporation said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is ramping up capital expenditures to support continued global manufacturing expansion plans.
- A water-type manufacturing building is expected to be ready by year-end and go live in 2029.
- Investments in R&D are being increased to support the innovation roadmap and key clinical development programs, including Omnipod 6 and fully closed loop for type 2 diabetes.
2 more points from Insulet Corporation's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Insulet Corporation said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Insulet Corporation said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Health Care Equipment and Supplies this season
- Globus Medical, Inc. (Q2 FY26)
Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.
- Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
- Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
- Zimmer Biomet Holdings, Inc. (Q2 FY26)
Zimmer Biomet Holdings, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $16,023, P/E 21.9. AI-powered earnings insights.
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Insulet Corporation and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Insulet Corporation Q2 FY26 results?
- Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24%. - Adjusted EPS expected to increase by more than 25% in 2026.
What is Insulet Corporation share price analysis?
Insulet Corporation currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 35.9 with a market cap of $9,881. Investors should review the full earnings analysis for detailed insights.
Is Insulet Corporation planning capital expenditure?
- The company is ramping up capital expenditures to support continued global manufacturing expansion plans.
Keep Insulet Corporation on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.